Half of original innovative Russian medicines were developed with the support of Skolkovo Foundation in recent years, said Kirill Kaem, Vice President, Executive Director of Вiomedical Technologies Cluster at the meeting of Skolkovo Foundation Council.
More than 1400 medicines were registered in the Russian Federation in 2014-2016. Out of them only 25 Russian drugs received marketing authorization certificates, of which only 4 can be described as innovative, said Mr. Kaem. Two medicines, Triazavirin, an antiviral drug, and Satereks, a hypoglycemic drug, were developed by Skolkovo residents.
“In 2017, we expect the successful completion of the late phases of clinical trials and registration of another eight products; seven products in 2018; and eight products in 2019,” said Kirill Kaem.
Since the end of 2013, the number of residents in the cluster has increased by more than 2.5 times to reach almost 400 companies (including 70 teams engaged in agro and industrial biotech). The revenues of residents grew almost 3-fold and, according to preliminary data for 2016, exceeded 4.5 billion rubles. Almost half of the teams work in the area of Pharma and Regenerative Medicine; 28% in medical instruments and devices; 17% in agro and industrial biotech; and 8% of companies in the cluster work on bioinformation projects.